Sign in
Taking people in United StatesPhase 1

Comparative Pharmacokinetics and Pharmacodynamics of Synthetic Nicotine

Key facts

Who runs it
University of California, San Francisco
Where
San Francisco, United StatesSee the site
Trial code
Status
Recruiting
Phase
Phase 1
People taking part
18 people, planned
Started
6 Dec 2024
Expected to end
May 2027
Type of study
Interventional, 3 groups
Treatments tested
  • (S)-Nicotine
  • (R)- nicotine
  • Racemic nicotine
Record updated
14 May 2026

Who can take part

Age
21 years to 65 years
Sex
Women and men
Healthy volunteers
Can take part
Show the full registry criteria (3)Hide the full registry criteria

Who can take part

  • Healthy on the basis of medical history and limited physical examination
  • Current regular user of E-Cigarettes (≥ 15 days in the past 30 days)

Who cannot take part

  • • Medications; Use of medications that are inducers of nicotine metabolizing enzyme CYP2A6 (Example: rifampicin, carbamazepine, phenobarbital, and other anticonvulsant drugs); Use of sympatholytic medications for cardiovascular conditions including hypertension (Example: beta and alpha-blockers); Concurrent use of nicotine-containing medications (Example: nicotine patch, lozenge, gum); Any stimulant medications (example: Adderall) generally given for ADHD treatment; Pregnancy; Pregnancy (self-reported and urine pregnancy test); Breastfeeding (determined by self-report); Women of childbearing potential must be using an acceptable method of contraception; Inability to read and write in English; A known propylene glycol/vegetable glycerin allergy; Uncomfortable with getting blood drawn

Eligibility questionnaire

From the criteria published for this trial, to help you prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.

  • Age
  • Nicotine dependence or nicotine vaping

This trial is currently available in United States.

  • Zuckerberg San Francisco General Hospital (ZSFG)San Francisco, United StatesContact: Lisa LawrenceTaking people

About the trial

What the trial wants to find out

In a crossover study, experienced electronic cigarette users will vape 3 different forms of nicotine: natural (derived from tobacco), synthetic, or a 50:50 mixture of both natural and synthetic. The investigators will compare nicotine metabolism, cardiovascular effects, patterns of self-administration, and participants' feelings of craving/withdrawal and enjoyment.

The 3 groups in the trial

  • S-nicotine (tobacco) as the starting conditionTreatment being tested

    Participants will spend 8 hours in the hospital research ward where they will vape e-liquid containing 100% (S)-nicotine.

    Treatment: (S)-Nicotine, (R)- nicotine, and Racemic nicotine

  • R-nicotine (synthetic) as the starting conditionTreatment being tested

    Participants will spend 8 hours in the hospital research ward where they will vape e-liquid containing 100% (R)-nicotine.

    Treatment: (S)-Nicotine, (R)- nicotine, and Racemic nicotine

  • Racemic (50:50 S- and R- nicotine) as the starting conditionTreatment being tested

    Participants will spend 8 hours in the hospital research ward where they will vape e-liquid containing 50% (S)-nicotine and 50% (R)-nicotine.

    Treatment: (S)-Nicotine, (R)- nicotine, and Racemic nicotine

Next steps

For your doctor

Doctor ask sheet

A PDF for your doctor: what this trial tests, who can take part, and 2 eligibility questions with room for answers and notes.

Download the PDF

PDF, US Letter, 1 to 2 pages. A4 size

For the study team

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Criteria questions
Built from NCT05962229, who can take part
Record updated
14 May 2026